An intravenous blood clot preventer developed by The Medicines Company should not be approved, according to an initial review by the U.S. Food and Drug Administration, which said data did not show that the product was as good as or superior to a rival drug. The review, posted on the FDA’s website on Monday, comes two days ahead of a meeting of outside experts who will recommend whether the drug should be approved. The FDA is not required to follow the recommendations of its advisors but typically does so.
Help employers find you! Check out all the jobs and post your resume.
